Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial.
Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial.
复制标题
DOI：
10.1186/s12888-016-0744-6
复制
发表时间：
2016-02-25
期刊：
影响因子：
4.4
通讯作者：
Cheung E
中科院分区：
文献类型：
--
作者：
Chien WT;Mui J;Gray R;Cheung E
目前的精神分裂症护理实践指南建议，抗精神病药物对于患者的长期维持治疗至关重要，但他们不坚持使用这种药物仍然是预防复发的主要障碍。这项研究评估了基于动机访谈的依从疗法对精神分裂症谱系障碍患者的效果。这项随机对照试验对 134 名患有精神分裂症谱系障碍的门诊患者进行；其中 67 人接受了六次坚持治疗（除常规护理外），67 人仅接受常规精神科护理。参与者的结果指标包括症状严重程度、用药依从性、住院率、对疾病/治疗的了解以及功能。坚持治疗组报告称，在 18 个月内，症状严重程度 (p < 0.003)、对疾病/治疗的了解 (p < 0.001)、功能 (p < 0.005)、再住院时间 (p < 0.005) 和药物依从性 (p < 0.005) 都有显着改善与单独的常规护理相比，随访。基于动机访谈的依从疗法可能是治疗依从性较差的早期精神分裂症患者的有效方法。 ClinicalTrials.gov NCT01780116，注册日期 2013 年 1 月 29 日。
Current practice guidelines for schizophrenia care recommend that antipsychotic medication is essential for patients’ long-term maintenance treatment but their non-adherence to this medication is still a main obstacle to relapse prevention. This study evaluated the effects of a motivational-interviewing-based adherence therapy for people with schizophrenia spectrum disorders. This randomised controlled trial was conducted with 134 outpatients with schizophrenia spectrum disorders; 67 of them received a six-session adherence therapy (in addition to usual care) and 67 received usual psychiatric care alone. Participants’ outcome measures included symptom severity, medication adherence, hospitalisation rates, insight into illness/treatment, and functioning. The adherence therapy group reported significantly greater improvements in symptom severity (p < 0.003), insight into illness/treatment (p < 0.001), functioning (p < 0.005), duration of re-hospitalisations (p < 0.005), and medication adherence (p < 0.005) over 18 months follow-up, when compared with usual care alone. Motivational-interviewing-based adherence therapy can be an effective approach to treatment for people with early stage of schizophrenia who poorly adhere to medication regimen. ClinicalTrials.gov NCT01780116, registration date January 29, 2013.